89 results about "SUBCUTANEOUS TUMOR" patented technology

The present invention concerns compositions comprising and methods of identification and use of targeting peptides selective for cancer tissue, particularly prostate or ovarian cancer tissue. The method may comprise identifying endogenous mimeotopes of such peptides, such as GRP78, IL-11Rα and hsp90. Antibodies against such targeting peptides or their mimeotopes may be used for detection, diagnosis and / or staging of prostate or ovarian cancer. In other embodiments, the compositions and methods concern novel type of gene therapy vector, known as adeno-associated phage (AAP). AAP are of use for targeted delivery of therapeutic agents to particular tissues, organs or cell types, such as prostate or ovarian cancer. In still other embodiments, targeting peptides selective for low-grade lipomas may be used for detection, diagnosis and targeted delivery of therapeutic agents.

IMDs and methods are provided for electroporation treatment of subcutaneous tumors. In some embodiments, IMDs of the present invention may store and introduce chemotherapy drugs into the body prior to electroporation therapy. High frequency stimulation of tissue in or around the tumor may also be provided to increase tissue temperature prior to electroporation therapy. Still further, delivery of the electroporation therapy may be synchronized with cardiac qRs complex to avoid impeding normal cardiac rhythm. Algorithms to suspend therapy in the event of edema may also be incorporated.

The invention belongs to the field of microorganism animal cell system, and relates to an establishment method of a fluorescence visualization human hepatoma nude mice model which can self emit high strength red or green fluorescences and has the metastatic ability. After obtaining a human high-metastatic fluorescence hepatoma cell line HCCLM3-R, HCCLM3-G, HCCLM6-R and HCCLM6-G of fluorescence genes with high chromosome conformable degree, high fluorescence intensity and stable expression by using the method of pseudotype slow virus infection, hepatoma cells expressed by the fluorescences is placed beneath nude mice skin to establish a fluorescence visualization high-metastatic human hepatoma nude mice subcutaneous tumor model or subcutaneous fluorescence expression tumor tissues is placed in nude mice hepar to establish a fluorescence visualization high-metastatic human hepatoma nude mice hepar primary tumor model. The got model can be used as a tracer of animal in vivo hepatoma cells, and can be used for molecular mechanism study of hepatoma recurrence and metastatic and prophase therapeutic effect discrimination for new anti-hepatoma therapy and new anti-hepatoma drugs, etc.

The invention discloses microencapsulated human pancreatic carcinoma cells, and a preparation method and application thereof. The preparation method comprises the following steps of: adding suspension with human pancreatic carcinoma cells into Matrigel-containing sodium alginate solution; spraying into a calcium chloride solution in high voltage electrostatic environment to obtain microspheres; and performing ion exchange reaction on the microspheres and a sodium citrate solution, and thus obtaining the microencapsulated human pancreatic carcinoma cells. The obtained microencapsulated human pancreatic carcinoma cells have uniform size and the diameter of about 420mm. Cells in microcapsules are well proliferated, and grow in a three-dimensional way. The microencapsulated human pancreatic carcinoma cells are applied to subcutaneous tumor and in-situ tumor animal models, and have the advantages of high modeling success rate and quick tumor growth compared with the traditional tumor cell suspension injection method.

The invention relates to the field of liposome drug delivery, in particular to a curcumin active drug-loading liposome and a preparation method thereof. The curcumin active drug-loading liposome is prepared from the following components of curcumin, phospholipid, cholesterol (Chol), a metal ion salt solution and an external water phase buffer solution, wherein the weight ratio of the curcumin to total phospholipid (the sum of phospholipid and cholesterol) is 0.5-1:10, the metal ion salt solution can be a sulfate, gluconate or acetate solution of copper ions or zinc ions, and the concentrationof the copper ions or the zinc ions in the metal ion salt solution is 50-300 mM. The curcumin active drug-loading liposome and the preparation method thereof have the characteristics that a curcumin active drug-loading liposome preparation with petal-like conformation is successfully prepared for the first time, cell experiments show that the curcumin active drug-loading liposome preparation has stronger active oxygen production capability and stronger tumor cell inhibition activity, and tumor-bearing mouse experiments show that the preparation has remarkable subcutaneous tumor growth inhibiting and metastatic tumor progress relieving effects.

The invention relates to a glutamine metabolic inhibitor-containing liposome and a pharmaceutical composition and use thereof. The fat-soluble glutaminase allosteric site inhibitor and the antitumor activity in combination with other drugs are obviously improved. The pharmacological activity of a glutamine metabolic inhibitor is further enhanced by increasing the solubility of the poorly water-soluble glutamine metabolic inhibitor by a lipophilic part of the liposome and modifying the liposome adjunct such as polymethacrylate; through the screening optimization of a formula, the inhibition rate of tumor cells is increased and finally the preparation is evaluated through an animal subcutaneous tumor model; the experimental results show that the liposome can significantly improve the anti-tumor activity of the glutamine metabolic inhibitor and improve the animal survival rate.

The invention provides a method for constructing a lung tumor experimental animal model. The method comprises the following steps of: 1, feeding a dog with cyclosporin according to the weight ratio of the dog to cyclosporin of 10mg to 1kg 4 days before inoculation; 2, preparing canine transmissible venereal tumor (CTVT) tissue blocks; and 3, puncturing to a predetermined target part by using a 16G guide puncture needle, placing 2 to 3 CTVT tissue blocks into the puncture needle, arranging a sterile gelatin sponge strip behind the CTVT tissue blocks, pushing the tissue blocks into lung tissues by a needle core and pulling the needle out. In the method, CTVT cells are used as tumor strains, the tumor tissue blocks are prepared through subcutaneous tumor cell passage by using the characteristics of transplantability and genetic stability; in-lung planting is performed by a minimally invasive intervention method to establish a dog transplantable lung cancer model; and the model can be applied to related experimental researches such as growth, invasion, transfer and the like of large-sized animal lung tumors.

The invention provides a classification diagnostic kit for liver cancer Sorafenib personalized treatment. Gankyrin overexpression can obviously restrain cell death and subcutaneous tumor proliferation, caused by Sorafenib, but if hydroxychloroquine is combined, drug resistant reaction caused by Gankyrin overexpression is obviously restrained. The classification diagnostic kit can provide new reference for Sorafenib clinical application.

The invention provides a retractor of a rhinoplastic endoscope for nasal surgery. The retractor of the rhinoplastic endoscope comprises a long fixed plate. A first round tube and a second round tube facing to the same direction are disposed on the fixed plate. An endoscope probe penetrates through the first round tube, a cleaning injector is connected with the second round tube, and accordingly the nasal surgery can be performed visually. The problem that the nasal surgery can be performed only in blind state or half-blind state at present is solved, and the retractor is applicable to surgical treatments such as nasal plastic beauty and subcutaneous tumor resection.

Relating to the field of gene therapy, the invention provides a method for knockout of a high-risk human papillomavirus (HPV) E6E7 gene by zinc finger nucleases (ZFNs). According to a high-risk type HPV E6E7 gene sequence, the method designs ZFNs expression vectors of a targeted specific site to targetedly cut the HPVE6E7 gene sequence in cells, thereby knocking out a target gene. In corresponding subtype HPV infected cells, the ZFNs can significantly induce cell apoptosis and proliferation inhibition, and has no effect on other subtype HPV positive cells and HPV negative cells. Transfection of the ZFNs expression vectors in a subcutaneous tumor model of HPV positive cervical cancer cells can obviously inhibit the growth rate of subcutaneous tumors and alleviate tumors. The method for targeted knockout of the high-risk HPV E6E7 gene by ZFNs can efficiently destroy virus oncogenes at the DNA level so as to make HPV infected cells undergo apoptosis and proliferation inhibition, and has enormous treatment value to HPV infection related diseases, especially cervical intraepithelial neoplasias and other precancerous lesions.

The invention relates to a sciatic nerve ligation subcutaneous tumor-bearing rat model and application of the sciatic nerve ligation subcutaneous tumor-bearing rat model in screening of analgesic and anti-tumor medicine. Single-side sciatic nerve ligation is conducted on an adult Wistar rat subjected to hypodermic implantation of Walker256 tumor cell suspension, the pain degree of the rat is reflected through spontaneous pain, the mechanical pain threshold value and the hot pain threshold value, and the tumor growth situation is indicated through the body weight change, the tumor formation rate and the tumor size of the rat. After the to-be-detected medicine is applied to the animal model according to the required mode and dosage, and the effect of the to-be-detected medicine on the aspect of analgesia and tumor prevention is judged by observing changes of the indexes. The experimental animal model which has the lasting and stable pain characteristic and can visually measure the tumor growth situation of the tumor of the rat is used for exploring the mechanism of promoting tumor growth through pain and used for screening the novel analgesic and anti-tumor medicine. The new carrier is provided for research and development of the novel analgesic and anti-tumor medicine.

The invention relates to a stereoscanning mesoscopic photoacoustic imaging system for a subcutaneous tumor of a small animal. The system comprises a light source system, a multi-angle stereo-scanningsystem, a water tank, a photoacoustic detection system, a data acquisition system and an industrial controller. The light source system comprises a high-energy pulse laser producing a photoacoustic signal and a multi-arm fiber optics bundle guiding emitted light of the laser. The photoacoustic detection system comprises a high-frequency point focused ultrasound detector used for receiving a photoacoustic signal, wherein defocusing-type measurement of the high-frequency point focused ultrasound detector is utilized. The multi-angle stereo-scanning system comprises an imaging support used for placing an imaging target, an electrically-controlled elevating table, an electrically-connected translational table and an electrically-controlled rotary table equipped with the high-frequency point focused ultrasound detector. The electrically-controlled rotary table is fixed onto the electrically-connected translational table. The imaging support is fixed onto the electrically-controlled elevating table. Through the electrically-controlled rotary table and the electrically-connected translational table, stereoscanning operation on a three-dimensional space is conducted by the high-frequency point focused ultrasound detector.

The invention discloses a tool for rapidly measuring the subcutaneous tumor size of mice. The tool comprises a measurement handle, wherein a limiting adjusting sliding chute is arranged at the upper part of the measurement handle, a measurement slider is mounted on the limiting adjusting sliding chute, an L-shaped forwards extending support arm is arranged at the front side of the measurement slider, a movable measurement clamp is fixed to the forwards extending support arm, a fixed measurement clamp fixed to the measurement handle is arranged at the opposite side of the movable measurement clamp, a row of longitudinal laser range finders is arranged in front of the fixed measurement clamp, a horizontal laser range finder is arranged on the inner wall of the fixed measurement clamp, while the movable measurement clamp and the fixed measurement clamp tightly clamp the subcutaneous tumor of the mice, the longitudinal laser range finders and the horizontal laser range finder respectively calculate the maximal transverse diameter in the vertical direction of the tumor and the maximal diameter in the horizontal direction of the tumor. With the tool, the problems that when a vernier caliper is used for measuring the tumor size in the traditional method, the operation is inconvenient and the data error is large, are solved, in addition, the whole tool is portable and convenient, and the cost is low.

The invention discloses a method for inhibiting hepatoma carcinoma nude mouse transplantation tumor capacity through silent secretory clusterin. The method includes the two steps of interference and detection. The method has the advantages that the method is simple and efficient, and it is clearly shown that the silent secretory clusterin can obviously inhibit the human hepatoma carcinoma nude mouse subcutaneous tumor formation capacity. It is effectively shown that the transcription of the silent secretory clusterin prolongs the incubation period of a human hepatoma carcinoma cell tumor-bearing nude mouse model. It is effectively shown that the silent secretory clusterin reduces the hepatoma carcinoma nude mouse transplantation tumor growth speed. Through protein and gene analysis, it is effectively shown that the silent secretory clusterin enables the expression level of the silent secretory clusterin in a hepatoma carcinoma nude mouse transplantation tumor and mRNA of the silent secretory clusterin to be smaller than those of a blank control group and a negative control group.

The invention discloses a subunit nano vaccine for preventing and treating nasopharyngeal carcinoma and a preparation method of the subunit nano vaccine. A nanoparticle is specifically disclosed, which comprises an EBNA1 [delta]GA protein, an immunoadjuvant, poloxamer and a polyphenol substance, and the EBNA1 [delta]GA protein is a recombinant protein obtained by deleting a repeat sequence of glycine-alanine in an EBNA1 protein. The invention also discloses the method for preparing the nanoparticle. The nanoparticle prepared by the invention has regular morphology, a round shape, a smooth surface, and good dispersibility, and does not have the phenomena of obvious adhesion, breakage, collapse, etc.; the EBNA1 [delta]GA protein and the immunoadjuvant in the nanoparticle have a high encapsulation rate; after applied to annimals, the nanoparticle can produce strong humoral immunity, significantly enhance cellular immunity, and has better prevention and treatment effects than a free-form antigen / adjuvant mixed injection and an existing vaccine containing an aluminum adjuvant in a mouse subcutaneous tumor model; and the subunit nano vaccine has great application prospects.

The invention discloses Chinese medicinal ointment for treating hyperthyroidism, scrofula, subcutaneous tumor and mastadenoma and a preparation method thereof. The Chinese medicinal ointment contains raw medicaments such as monkshood, aconite, short-pedicel aconite root, nux vomica, centipede, realgar and potassium nitrate. When the ointment is used, the ointment is directly stuck to a tumor position, a patch is changed every three days, the lump is separated after three to five patches of ointment are stuck, the wound is scared after separation, and the original skin is recovered after the scar is removed, so the scar is not left. The ointment has a good treatment effect on hyperthyroidism, scrofula, subcutaneous tumor, mastadenoma and the like; by adopting an external sticking method, toxic or side effect of an administration method for other Chinese medicaments and defects of various uncomfortable symptoms are well avoided; the ointment has an obvious treatment effect, and does not have toxic or side effect; and a preparation method for the ointment is easy to operate, the content of active ingredients is high, and the making cost is low.

The locally applied medicine composition for treating subcutaneous tumor includes As2O3 in effective amount and pharmaceutically acceptable carrier. It is used in treating primary skin cancer, melanin cancer or metastatic subcutaneous cancer.

The invention relates to an optical-image-based non-invasive naked mouse tumor receptor density determining method. Receptor detection expressing means and methods in existing scientific experiments can be only used for qualitative or half quantitative measurement but cannot calculate receptor density values accurately. The method includes the steps of 1, establishing a naked mouse subcutaneous tumor model; 2, injecting an optical mark target probe to perform dynamic optical acquisition; 3, marking an ROI (region of interest); 4, performing singular value decomposition; 5, fitting data to obtain a BP value; 6, calculating an available receptor density. The optical-image-based non-invasive naked mouse tumor receptor density determining method is a method by which available receptor density information of tumor regions can be obtained without obtaining living tissues invasively, thereby being simpler and more convenient and accurate than previous methods.

The invention discloses a combined drug for treating colorectal cancer. The combined drug is prepared from diosgenin, baicalein A, fucoidan and psoralen. An in-vivo animal experiment shows that the combination application of the diosgenin, the baicalein A, the fucoidan, the psoralen, Binimetinib and cetuximab has a significant synergistic effect on the treatment of the colorectal cancer, the diosgenin can affect the blood supply of tumor by inhibiting the proliferation activity of endothelial cells, and finally inhibit the proliferation of a subcutaneous tumor model, meanwhile, the diosgenin can inhibit the metastasis of rectal cancer through the direct action, and has the synergistic interaction effect by combining with the cetuximab; and the purpose of tumor prevention can be achieved bythe psoralen through multiple mechanisms of calcium antagonistic effect, multi-drug resistance reversing effect, estrogen-like effect, photosensitive activity effect, apoptosis inducing , mitochondrial degeneration inducing and the like.

The invention discloses application of macrocarpal I to preparation of an anti-tumor drug. In an experiment, the inventor finds that the macrocarpal I can effectively inhibit proliferation in vitro orinvasion of colorectal cancer cells, can inhibit the clonality of the colorectal cancer cells, can reduce the growth rate of the subcutaneous tumor of a naked mouse and has certain specificity to thecolorectal cancer cells. In addition, the macrocarpal I is extremely high in safety and expected to be a natural anti-tumor micro-molecular compound applied to the treatment of the metastatic colorectal cancer.

The invention discloses a circular RNA (Ribonucleic Acid) and application thereof. The cDNA (complementary deoxyribonucleic acid) sequence of the circular RNA is disclosed by SEQ ID NO:1, and the structure of the circular RNA is an end-to-end circular structure formed in a way that a nucleotide sequence disclosed by SEQ ID NO:1 is sheared after transcription is carried out. Through QPCR (quantitative polymerase chain reaction), an expression difference situation of circDLC1 in hepatocellular carcinoma tissues and para-carcinoma tissues is detected so as to discover that the expression of the circDLC1 in the hepatocellular carcinoma tissues is obviously lowered than the expression in the para-carcinoma tissues, and the circDLC1 can be indicated to be used for hepatocellular carcinoma diagnosis. A migration and invasion experiment can prove that after the circDLC1 is subjected to overexpression, hepatocellular carcinoma cell migration and invasion ability is obviously inhibited so as toindicate that the circDLC1 can be used as a treatment target spot for diagnosing and treating the hepatocellular carcinoma cells; and a naked mouse subcutaneous tumor model, a naked mouse hepatocellular carcinoma in situ model and a naked mouse advanced stage transferring model are constructed to prove that circDLC1 overexpression has an inhibition function for proliferation, invasion and transferof hepatocellular carcinoma cells in the body of the naked mouse.

The invention provides an application of PPM-18 in inducing apoptosis of bladder cancer cells by activating intracellular reactive oxygen species (ROS). The PPM-18 significantly inhibits the viabilityof bladder cancer cell; PPM-18 promote cell apoptosis by inducing ROS production in bladder cancer cells; and the PPM-18 significantly inhibits the growth of human bladder cancer subcutaneous tumorsand prolongs the survival cycle of mice with subcutaneous tumors. At the same time, PPM-18 has very lower toxicity to normal human hepatocyte. In addition, PPM-It can be synthesized chemically, with lower cost, and can be used as a new drug for treating bladder cancer.

A rotary water jet device for surgery comprises a high-pressure water pump, an installation cylinder and a handle arranged on the upper portion of the outer side of the installation cylinder. The installation cylinder is internally provided with an upper bearing block, a lower bearing block, a drive motor and a rotary sealing connection device. The upper bearing block and the lower bearing block are internally and rotationally connected with a hollow transmission shaft through a first bearing and a second bearing respectively, and a connection hole is formed in the center of the upper end of the hollow transmission shaft. The lower end of the rotary sealing connection device and the upper end of the hollow transmission shaft are coaxially fixed and in sealed connection, and the lower end of the hollow transmission shaft is provided with a rotary jet device located on the lower portion of the installation cylinder. The rotary water jet device is novel in design, compact in structure, convenient to operate, good in sealing performance, safe and reliable, the radius of jet can be adjusted according to the size of lipomas or fibromas so as to cut off lipomas or fibromas at a time, operation time is greatly shortened, and the rotary water jet device does not need to be moved in the operation process and is suitable for being operated by doctors with different experience.

The invention discloses application of CRTAC1 as a target in preparation of a drug for diagnosing and treating lung adenocarcinoma, and the CRTAC1 can be used as a target for growth, proliferation, invasion and migration of lung adenocarcinoma cells. The CRTAC1 has the following functions: the overexpressed CRTAC1 inhibits the proliferation of lung adenocarcinoma cells, subcutaneous tumor formation capacity of nude mice, the migration and invasion of the lung adenocarcinoma cells and the formation of lung metastatic lesions in the nude mice.

The invention provides the Zidovudine-conjugated quinoline compound N-((1-(2-(hydroxy-methyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-tetrahydrofuran-3-yl)-1H-1,2,3-triazol-4-yl)methyl)-6-(4b,8,8-trimethyl-4b,5,6,7,8,8a-hexahydrodibenzo[a,c]phenazin-2-yloxy)hexanamide. The compound can selectively kill hepatoma cells, especially hepatoma cells with hepatitis B, and inhibit the growth of subcutaneous tumors in mice, but has no significant toxicity to normal liver cells. Experiments confirm that the compound has an anti-hepatoma effect and can be used in preparation of anti-hepatoma drugs.

The invention discloses a human hepatocellular carcinoma cell line with portal vein transfer potential (CCTCC NO: C200913) and a cell line construction method. After subcutaneous transplantable tumors formed by the cells is inoculated to a nude mouse liver to form tumors, the formation of portal vein cancer emboli can be detected and strong forming ability of portal vein cancer emboli is generated. The cell line construction method comprises the following steps of: (1) transplanting cancer embolus tissues of the human liver cancer portal vein in subcutaneous nude mouse skin; (2) performing passage on transplanted subcutaneous tumors; (3) inoculating the nude mouse liver by using the transplanted subcutaneous tumors of the fifth generation; (4) performing primary culture by using liver neoplasm to construct the line. The construction method has the advantages that: CSQT-2 cells are cultured by taking materials from the human portal vein cancer embolus tissues and transplanting nude mouse liver species in situ, so that the cell line has strong formation ability of portal vein cancer emboli, unparallel advantages in forming mechanism and tendency growing mechanism of the liver cancer portal vein cancer emboli compared with other conventional liver cancer cell lines, and wide application prospect.

The invention belongs to the technical field of pharmacy, and relates to a novel pharmaceutical application of cinobufotalin, in particular to application of the cinobufotalin in preparation of an anti-tumor immune drug. Mouse colon cancer subcutaneous transplantation tumor model animal experiments prove that the cinobufotalin has a good effect on resisting tumor immunity, has no adverse reaction, can relieve mouse colon cancer subcutaneous tumor induced by colon cancer cells, and provides a good application prospect for treating, relieving or eliminating tumor immune escape and improving body immunity.

The invention relates to the technical field of biomedical materials, in particular to a double-layer conductive microneedle patch for treating subcutaneous tumors and a preparation method and application thereof.The double-layer conductive microneedle patch is composed of a conductive microneedle substrate without a target drug and a double-layer microneedle tip containing the target drug, and the microneedle tip is prepared from an easily-soluble polymer matrix; the micro-needle substrate and the part, close to the substrate, of the micro-needle tip are prepared from a degradable polymer matrix and a conductive polymer material, so that the micro-needle has excellent biocompatibility and has no potential irritation and immunogenicity; the substrate and the part, close to the substrate, of the microneedle tip are made of a conductive polymer material, so that good conductivity is achieved, cell membrane permeability is improved through electroporation, and the biological agent or medicine absorption rate is increased; the proliferation of tumor cells is effectively inhibited; through the microneedle technology, target medicine can be intensively distributed at the tip of the microneedle, the local effective medicine concentration is improved, and the medicine cost is saved; the method has the advantages of high precision, large scale, economy and high efficiency.